

Barbara J. Winslow and Mark D. Cochran
Serial No.: Not Yet Known
Filed: Herewith

- 39³. (New) The recombinant virus of claim 38² which comprises at least three foreign nucleic acids, each inserted within a non-essential region of the viral genome.
- 40⁴. (New) The recombinant virus of claim 38² which comprises four foreign nucleic acids, each inserted within a non-essential region of the viral genome.
- 41⁵. (New) The recombinant virus of claim 37¹, wherein the virus is raccoonpox virus, a swinepox virus, or a feline herpesvirus.
- 42⁶. (New) The recombinant virus of claim 37¹ comprising more than one foreign nucleic acid, wherein each foreign nucleic acid is inserted into the same nonessential region.
- 43. (New) The recombinant virus of claim 37¹ comprising more than one foreign nucleic acid wherein all such foreign nucleic acids are not inserted into the same nonessential region.
- 44⁸. (New) The recombinant virus of claim 37¹ further comprising a foreign nucleic acid encoding an immunogen derived from a pathogen.
- 45⁹. (New) The recombinant virus of claim 44⁸, wherein the pathogen is a feline pathogen, a rabies virus, Chlamydia, Toxoplasmosis gondii, Dirofilaria immitis, a flea, or a bacterial pathogen.
- 46¹⁰. (New) The recombinant virus of claim 45⁹, wherein the feline pathogen is feline immunodeficiency virus (FIV), feline leukemia virus (FeLV), feline infectious peritonitis virus (FIP), feline panleukopenia virus, feline calicivirus, feline reovirus type 3, feline

Sub C 2

Sub D 1

a

Barbara J. Winslow and Mark D. Cochran
Serial No.: Not Yet Known
Filed: Herewith

rotavirus, feline coronavirus, feline syncytial virus, feline sarcoma virus, feline herpesvirus, feline Borna disease virus, or a feline parasite.

¹¹
--~~47~~. (New) The recombinant virus of claim ~~37~~¹, wherein at least one foreign nucleic acid comprises a promoter for expressing the foreign nucleic acid.

¹²
--~~48~~. (New) The recombinant virus of claim ~~37~~¹, wherein the expression of a least one foreign nucleic acids is under the control of a promoter ~~endogenous~~^{endogenous} to the virus.

¹³
--~~49~~. (New) The recombinant virus of claim ~~37~~¹ further comprising a foreign nucleic acid encoding a detectable marker.

¹⁴
--~~50~~. (New) The recombinant virus of claim ~~49~~¹³, wherein the detectable marker is E.coli beta galactosidase.

¹⁵
--~~51~~. (New) The recombinant virus of claim ~~46~~¹⁰, wherein the immunogen from a feline pathogen is FIV gag protease, a FIV envelope protein, a FeLV gag protease, or a FeLV envelope protein.

¹⁶
--~~52~~. (New) The recombinant virus of claim ~~37~~¹, wherein the virus is a feline herpesvirus and the a nonessential region is the glycoprotein G gene of feline herpes virus.

¹⁷
--~~53~~. (New) The recombinant feline herpesvirus of claim ~~48~~¹² designated S-FHV-031 (ATCC Accession No. VR-2604).

¹⁸
--~~54~~. (New) The recombinant virus of claim ~~37~~¹, wherein the virus is swinepox virus and the nonessential region is the larger Hind III to Bgl II subfragment of the Hind III M fragment of swinepox virus.

Barbara J. Winslow and Mark D. Cochran
Serial No.: Not Yet Known
Filed: Herewith

- Sub D3*
- 55.¹⁹ (New) The recombinant feline swinepox of claim 50¹⁴ designated S-SPV-246 (ATCC Accession No. VR-2603).
- 56.²⁰ (New) The recombinant virus of any of claim 37¹, wherein the portion of the CD28, CD80, or CD86 protein is the soluble portion of the protein.
- CONF.*
- 57.²¹ (New) The recombinant virus of claim 37¹, where the foreign nucleic acid encodes the feline CTLA-4 protein.
- 58.²² (New) A vaccine which comprising an effective immunizing amount of the recombinant virus of claim 37¹ and a suitable carrier.
- Sub D4*
- 59.²³ (New) The vaccine of claim 58²², wherein the effective immunizing amount of the recombinant virus is an amount between about 1×10^5 pfu/ml and about 1×10 cfu/ml.
- 60.²⁴ (New) The vaccine of claims 58²² which further comprises an admixture with the recombinant virus an effective immunizing amount of an a second immunogen.
- 61.²⁵ (New) A method for enhancing an immune response in a feline which comprises administering to the feline an effective immunizing amount of the recombinant virus of claim 37¹.
- Sub D5*
- 62.²⁶ (New) A method for immunizing a feline which comprising administering to the feline an effective immunizing amount of the recombinant virus of claim 37¹.
- 63.²⁷ (New) A method for suppressing an immune response in a feline which comprises administering to the feline any effective suppressing amount of the recombinant virus of claim 56.²⁰

Barbara J. Winslow and Mark D. Cochran
Serial No.: Not Yet Known
Filed: Herewith

²⁸
--64. (New) The method of claim ~~61~~²⁵, wherein the administering comprises intravenous, subcutaneous, intramuscular, transmuscular, topical, oral, or intraperitoneal administration.

²⁹
--65. (New) The method of claim ~~65~~²⁷, wherein the feline is the recipient of a transplanted organ or tissue or is suffering from an immune response.

³⁰
--66. (New) A method for suppressing an immune response in a feline which comprises administering to the feline an antisense nucleic acid capable of hybridizing to and inhibiting translation of: (a) a feline CD28 mRNA transcript, (b) a feline CD80 transcript, or (c) a feline CD86 mRNA transcript the antisense nucleic acid being present in an amount effective to inhibit translation and thus suppress the immune response in the feline.

³⁰
--67. (New) A method for reducing or abrogating a tumor in a feline which comprises administering to the tumor in the feline a recombinant virus of claim ~~27~~³¹, wherein the nucleic acid encodes a feline CD80 protein, a feline CD86 protein or a combination thereof in an amount effective reduce or abrogate the tumor.

³¹
--68. (New) The method of claim ~~67~~³⁰, wherein the recombinant virus further comprises, and is capable of expressing, a feline tumor associated antigen and the administration is effected systemically.

³²
--69. (New) The recombinant virus of claim ~~27~~³¹, further comprising a nucleic acid encoding feline immunodeficiency virus genome or a portion thereof.

³³
--70. (New) The recombinant virus of claim ~~27~~³¹, further

Barbara J. Winslow and Mark D. Cochran
Serial No.: Not Yet Known
Filed: Herewith

comprising a nucleic acid encoding feline leukemia virus genome or a portion thereof.

1 concurred
Sub 3
--71. (New) The recombinant virus of claim 69, further comprising a nucleic acid encoding feline IL12, p35 or p40.

--72. (New) The recombinant virus of claim 70, further comprising a nucleic acid encoding feline IL12, p35 or p40.

3629
--73. (New) A vaccine which comprises an effective immunizing amount of the recombinant virus of claim ~~69~~³² and a suitable carrier.

3730
--74. (New) A vaccine which comprises an effective immunizing amount of the recombinant virus of claim ~~70~~³³ and a suitable carrier.

REMARKS

Claims 1-36 were pending in the subject application. By this amendment applicants have canceled claims 1-36 without prejudice or disclaimer, and added new claims 37-74. Accordingly, upon entry of this Amendment, claims 37-74, will be pending and under examination.

Applicants maintain that new claims 37-74 raise no issue of new matter. According, the entry of this Preliminary Amendment and the allowance of the claims now pending in this application are respectfully requested.